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All patients have the right to expect to receive the best therapeutic
means available to reduce their suffering. Recent evaluation of the
French ministerial 3-year plan for the fight against pain by the
French Society of Public Health (http://www.sfsp-france.org/Plan-
Lutte-Douleur/Plan-Lutte-Douleur.htm) and observations of cur-
rent practice show that the information and training of health
professionals in this area should be continued. The necessity to
fight against cancer pain has only recently become a priority. In
1996 a working group, set up by the French National Federation of
Cancer Centres (Fe ´de ´ration Nationale des Centres de Lutte Contre
le Cancer–FNCLCC), published clinical practice guidelines for
pain management in adult and paediatric patients with cancer
(Krakowski et al, 1996). These guidelines now require updating,
but in this document only the pharmacological treatment of pain
arising from excess nociception in adults with cancer is covered.
The other sections of the original guideline are currently being
updated in the context of a collaboration between the FNCLCC and
the SETD (Society for the Study and Treatment of Pain (Socie ´te ´
d’Etude et de Traitement de la Douleur) French section of the
International Association for the Study of Pain (IASP) subgroup
on cancer pain).
OBJECTIVES
The main objective of this paper is to provide physicians with a
reference document for the management of cancer pain in adults.
Another objective is to provide guidance on the use of the different
opioids now available since the number of drugs available has
increased, as have drug formulations and modes of delivery.
Another objective is also to remove all fears about the risk of
addiction in patients with cancer.
The treatment of pain other than nociceptive pain (especially
neuropathic pain), pain evaluation, the use of coanalgesics and
pain management requiring specialist teams, will be covered in the
updates currently being developed from the original document
published in 1996 (Krakowski et al, 1996).
METHODS
The section on ‘analgesic treatment’ in the document published in
1996 was examined by the working group to identify questions that
required updating. These questions and the relevant key words
were used to develop a search strategy that was used to search
Medline
s, and for particular questions, Embase
s from January
1994 to March 1999, for relevant references, published in English
or French. Additional references were provided by members of the
working group.
After selection and critical appraisal of the articles, the working
group proposed the ‘Standards’ and ‘Options’ for the management
of nociceptive cancer pain in adult patients. Recommendations
based on the best available evidence or expert agreement were
developed using the SOR methodology (Fervers et al, 2001).
When all the members of the working group agree, based on the
best available evidence, that a procedure or intervention is
beneficial, inappropriate, or harmful, it is classified as a ‘Standard’,
and when the majority agree, it is classified as an ‘Option’ (Table 1).
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situation. ‘Recommendations’ provide additional information that
enable the available options to be ranked using explicit criteria
(e.g. survival, toxicity) with an indication of the level of evidence.
These recommendations help clinicians to select an appropriate
option. Thus, clinicians can make choices for the management of
patients using this information and taking into consideration local
circumstances, skills, equipment, resources and/or patient pre-
ferences. The adaptation of the SOR to the local situation is
allowable if the reason for the choice is sufficiently transparent and
this is crucial for successful implementation. Inclusion of patients
in clinical trials is an appropriate form of patient management in
oncology and is recommended frequently within the SORs,
particularly in situations where only weak evidence exists to
support a procedure or an intervention.
The type of evidence underlying any ‘Standard’, ‘Option’o r
‘Recommendation’ is indicated using a classification developed by
the FNCLCC based on previously published methods. The level of
evidence depends not only on the type and quality of the studies
reviewed, but also on the concordance of the results (Table 2).
When no clear scientific evidence exists, judgement is made
according to the professional experience and consensus of the
expert group (‘expert agreement’), but this is then validated by the
peer-review process. For this update, only a few randomised
clinical trials have been identified, and their conclusions are
generally weak. Thus, much of the information in this document
represents the ‘state of the art’ on this subject in France and is
supported by expert agreement. Much of the information in this
document is based on the World Health Organisation (WHO)
guidelines initially published in 1986 (World Health Organisation,
1986).
The integral version of this document was peer reviewed by
independent experts, and their comments were taken into
consideration in the preparation of the final document. The SOR
guidelines are considered to be validated when the members of the
working group give their agreement for publication. This integral
version is available on the FNCLCC web site (http://www.fnclcc.fr).
A summary version was prepared in French (Krakowski et al,
2003) based on the full text version, and this is the English version
of that summary.
General principles
Analgesic treatment should be constantly adapted to the clinical
situation in which it is used (standard, expert agreement). In
addition to the criteria used to choose the appropriate treatment
(patient age, performance status, past history, pain aetiology,
potential side effects, etc.), an understanding of the physiopatho-
logical mechanisms of the pain is essential (standard, expert
agreement).
The WHO analgesic ladder is used to classify three levels of pain
as summarised in Figure 1. The strategy originally developed by
WHO for the management of nociceptive pain in patients with
cancer is based around five essential principles and these remain
generally relevant today (standard, expert agreement):
 oral drug administration;
 drug administration at regular intervals;
 drug administration conforming to the three-step WHO ladder
(Figure 1);
 personalised administration;
 constant attention to detail.
Table 1 Definition of ‘Standards, Options and Recommendations’
Standards Procedures or treatments that are considered to be of benefit, inappropriate or harmful by unanimous decision, based
on the best available evidence
Options Procedures or treatments that are to be considered of benefit, inappropriate or harmful by a majority, based
on the best available evidence
Recommendations Additional information to enable the available options to be ranked using explicit criteria (e.g., survival, toxicity) with
an indication of the level of evidence
Nonopioid analgesics
for mild to moderate
pain
coanalgesics ±
Opioids for
moderate pain
+ nonopioids
± coanalgesics
Level 2
Opioids for moderate
to strong pain
± nonopioids
± coanalgesics
Level 3
Disappearance of pain
If pain persists
Pain
Level 1
Figure 1 Modified WHO analgesic ladder.
Table 2 Definition of level of evidence
Level A
There exists a high standard meta-analysis or several high standard randomised clinical trials that give consistent results
Level B
There exist good quality evidence from randomised trials (B1) or prospective or retrospective studies (B2). The results are consistent when considered together
Level C
The methodology of the available studies is weak or their results are not consistent when considered together
Level D
Either the scientific data do not exist or there is only a series of cases
Expert agreement
The data do not exist for the method concerned, but the experts are unanimous in their judgement
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to the patient. It should anticipate breakthrough pain and side
effects. It should be re-evaluated regularly (standard, expert
agreement).
The timing of progression from one step of the therapeutic
ladder to the next is dependent on the duration of action of the
analgesic and the intensity of the pain (standard, expert
agreement).
Two products of the same pharmacological class, with the same
kinetics (e.g., two sustained-release opioids), should not be
prescribed together (standard, expert agreement).
Coanalgesics can be used concurrently at each level in the WHO
analgesic ladder (standard, expert agreement).
The prescription of strong opioids as first-line analgesia should
be considered in patients with very severe pain (option, expert
agreement).
Nonopioid analgesics (WHO level 1)
Nonopioid analgesics should be used for mild to moderate pain
(standard, expert agreement). Nonopioid analgesics (WHO level 1)
can be combined with opioid analgesics (WHO levels 2 and 3)
(option, expert agreement).
Acetaminophen (1g every 4–6h) is recommended as first-line
treatment for mild to moderate pain (recommendation, expert
agreement). The maximum dose in the French product licence is
4g/day. Acetaminophen can cause hepatic toxicity if the daily
recommended dose is exceeded. This justifies cautious use in
patients with liver failure (recommendation, expert agreement).
The use of nonsteroidal anti-inflammatory drugs (NSAID) is
recommended for treating inflammatory pain, particularly bone
pain (recommendation, expert agreement). NSAIDs should not be
used with methotrexate (standard, expert agreement). When
NSAIDs are prescribed, the potential risk when used in conjunc-
tion with nephrotoxic (particularly cisplatin) or myelotoxic
chemotherapy should not be ignored (standard, expert agree-
ment). If gastrointestinal symptoms develop in patients taking
NSAIDs, the necessity to use an NSAID at all and/or the need for
gastroscopy and/or the prescription of a proton pump inhibitor
should be reviewed (standard, expert agreement).
COX2 inhibitors have not been evaluated in clinical trials of
patients suffering from cancer pain and they are not licensed for
use in cancer patients in France. Nefopam and floctafenin are not
indicated as first-line treatments for chronic cancer pain
(recommendation, expert agreement).
Dipyrone is not advised, except in specific situations, because of
the serious, unpredictable side effects that have been reported
(recommendation, expert agreement).
Classification of the opioids
Based on their analgesic efficacy, opioids are classed as ‘weak’ for
moderate pain (WHO level 2 — classified as prescription drugs in
France) and ‘strong’ for moderate to severe pain (WHO level 3 —
classified as special prescription drugs in France except for
buprenorphine and nalbuphine (prescription drug).
Opioids can be classed into three categories based on the type of
action they have on receptors: pure agonist, partial agonist–
antagonist or mixed agonist–antagonist. Drugs in different
categories should not be prescribed at the same time (standard,
expert agreement).
‘Weak’ opioid analgesics (WHO level 2)
‘Weak’ opioid analgesics should be used in patients with moderate
pain (standard, expert agreement).
Weak opioid analgesics can be used alone or in combination
with a level 1 analgesic (option, expert agreement). The following
products can be used: codeine, dextropropoxyphene, dihydroco-
deine, tramadol (option, expert agreement). There are no absolute
criteria to guide the selection of the different drugs.
Tramadol should not be combined with monoamine oxidase
inhibitors (standard, expert agreement). Tramadol should be used
with caution in patients with a risk of epilepsy and when used in
combination with antidepressants (recommendation, expert agree-
ment).
Dextropropoxyphene should not be used in combination with
carbamazepine as it will induce an increase in the plasma
concentration of carbamazepine (recommendation, expert agree-
ment).
Constipation should always be anticipated in patients receiving
codeine (standard, expert agreement).
Strong opioid analgesics (WHO level 3)
Strong opioid analgesics should be used in patients with moderate
to severe pain (standard, expert agreement).
Morphine Except in specific situations, oral morphine is the first-
line WHO level 3 opioid of choice (standard, expert agreement).
Oral morphine should be given without delay to patients whose
pain is uncontrolled by step 1 and 2 treatments (standard, expert
agreement).
Morphine should be prescribed in an oral form, either as tablets
or capsules of immediate-release morphine sulphate, as tablets or
capsules of sustained-release morphine sulphate, or as morphine
hydrochloride solution (standard, expert agreement).
In all patients treated previously with another strong opioid, the
starting dose for morphine should be calculated using equianal-
gesic dose ratios (standard, expert agreement).
In patients receiving baseline treatment with opioids, an
immediate-release formulation must be prescribed concurrently
for the treatment of breakthrough or incident pain (standard,
expert agreement).
It is advisable to be cautious by prescribing doses at the lower
end of the equianalgesic dose range and providing rescue doses as
needed, rather than immediately subjecting the patients to doses at
the upper limit of the range (standard, expert agreement).
When oral administration is impossible, the preferred routes are
transdermal (e.g. fentanyl), or continuous parenteral administra-
tion with patient-controlled analgesia (e.g. morphine) (option,
expert agreement). The choice of dose should take into
consideration equianalgesic dose ratios (recommendation, expert
agreement).
The other routes of administration for morphine and the other
opioids are rarely indicated. They should be used taking into
consideration the benefit to risk ratio, the training of the personnel
involved (including close family and friends), and the constraints
of the follow-up, particularly for patients at home (recommenda-
tion, expert agreement).
Treatment with opioids (particularly oral morphine) should
never be stopped abruptly (standard, expert agreement). No
specific protocol for reducing the dose of opioids has been
validated. Dose reduction should be in steps of 30–50% over about
a week, depending on the clinical situation (reappearance of pain,
development of withdrawal symptoms, etc.) (recommendation,
expert agreement).
Other opioids Although buprenorphine is used in some coun-
tries, it cannot be recommended as a WHO level 3 opioid since
other opioids have become available (recommendation, expert
agreement).
The use of fentanyl patches at 25mgh
1 is one therapeutic
option for the initiation of opioid treatment in patients with stable
pain. This is appropriate for patients who do not need frequent
breakthrough doses and do not have intense pain that requires
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useful in the following situations (option, expert agreement):
 oral administration impossible because of uncontrolled nausea
and vomiting;
 risk of bowel obstruction;
 poor digestive absorption: fistula; short or irradiated small
intestine; gastrointestinal damage following surgery; severe
diarrhoea; etc.;
 moderate chronic renal failure (fentanyl is mainly metabolised
through a hepatic route);
 to reduce the number of tablets in patients distressed by a large
number of medications.
Hydromorphone is indicated for patients with severe cancer
pain when there is resistance or intolerance to morphine (option,
expert agreement).
Oxycodone is another alternative to oral morphine for the
treatment of severe cancer pain when there is resistance or
intolerance to morphine (option, expert agreement).
Pethidine has no place as a WHO level 3 opioid since other
opioids have become available (option, expert agreement).
Transmucosal fentanyl should only be used to treat break-
through pain as a complement to baseline opioid analgesia in
patients with chronic cancer pain. The high cost of this treatment
should be taken into consideration (option, expert agreement).
Titration The initial and subsequent dose titration (dose
readjustment) of WHO level 3 opioids can be undertaken with a
sustained-release preparation in combination with an immediate-
release form, or with an immediate-release form only, particularly
in ‘frail’ patients (option, expert agreement).
At the time of initial titration, at least once-daily self-assessment
(particularly for patients at home) or assessment by a health
professional is necessary to judge the analgesic efficacy and to
detect any side effects (standard, expert agreement).
There is no upper limit to the dose of a pure agonist opioid as
long as the side effects can be controlled (standard, expert
agreement).
Rescue doses should be calculated based on the daily opioid
dose (standard, expert agreement).
Each immediate-release opioid rescue dose should correspond
to 10% of the daily dose of sustained-release opioid (recommenda-
tion, expert agreement).
Patients who have uncontrolled pain can take a rescue dose
every hour for up to 4h, before consulting a physician. If pain
relief is not obtained after the four consecutive doses, the patient
should be reassessed, in a hospital if necessary (recommendation,
expert agreement).
Prescription Outside the hospital setting, prescriptions for
opioids should be written out in full on security prescription
forms. All oral forms of morphine and most opioids can be
prescribed for a maximum of 28 days. For injectable forms, the
prescription is restricted to 7 days or to 28 days when used in an
infusion system.
In hospital, it is not obligatory to write the prescription on a
security prescription form. In practice, the procedure will vary
depending on local practice.
The loss or theft of a security prescription form should be
declared. In France, this declaration should be made to the
departmental medical supervisory council, the regional pharmacy
inspectorate as well as to the local police.
Side effects of oral morphine
All opioids have similar side effects. The ‘Standards, Options, and
Recommendations’ below relate to oral morphine.
There is wide inter- and intrapatient variation in the occurrence
of side effects. The occurrence of side effects is not necessarily
related to an overdose. Miosis is a sign of morphine usage, but it is
not a sign of overdosage. The risk of overdose is low in patients
with cancer pain, when they are followed-up and evaluated
regularly and when they receive morphine continuously for a long
period. Psychological dependence is rare in patients with cancer.
Tolerance and physical dependence are not problems in patients
treated with oral morphine for cancer pain. The prescription
should be uninterrupted. The coprescription of an opioid receptor
agonist and an antagonist should be avoided to prevent physical
dependence. Drowsiness occurs principally during the treatment
titration phase and usually disappears within a few days. In
patients with persistent or recurrent drowsiness, the presence of
metabolic disorders or potentiation by other drugs should be
considered (standard, expert agreement). However, if the mor-
phine is found to be the cause, its dose should be reduced or the
drug changed (rotation) (option, expert agreement). Dose reduc-
tion should be preferred if the pain is well controlled (recommen-
dation, expert agreement).
With the exception of constipation, other side effects tend to
disappear in the first few days or weeks of treatment with oral
morphine. The patient should be informed about the possibility of
side effects, particularly the most frequent: constipation, nausea,
drowsiness (standard, expert agreement).
A laxative, to prevent constipation, should be prescribed during
the treatment period and this should be associated with advice on
diet and hydration (standard, expert agreement).
In patients with nausea and vomiting during treatment, other
possible causes should be excluded first. If this persists, an
antiemetic should be prescribed for a few days (standard, expert
agreement).
There is no contraindication for the prescription of opioids in
patients with asthma and/or respiratory failure (standard, expert
agreement).
In patients receiving oral morphine who have resistant side
effects, the options are either to change the administration route or
to change the opioid (rotation, see below):
 in the presence of very unstable, intense pain, preference should
be given to intravenous or subcutaneous patient-controlled
analgesia (option, expert agreement);
 in other situations (stable and/or moderate pain), rotation and/
or intravenous or subcutaneous patient-controlled analgesia are
possibilities (option, expert agreement).
Opioid rotation
Opioid rotation is defined as the substitution of one opioid by
another and is justified if this results in an improved benefit to risk
ratio. The main indication for opioid rotation is the occurrence of
resistant side effects (particularly disorders of cognitive function,
hallucination, myoclonus and nausea), despite adequate sympto-
matic treatment (usually in patients receiving high doses of
opioids) (standard, expert agreement).
Another indication for opioid rotation is the rare occurrence of
resistance to opioids, defined not only by an absence of efficacy,
but also by an absence of side effects despite a rapid increase in
opioid dose (standard, expert agreement).
Opioid rotation is possible between all the pure agonists:
morphine, fentanyl, hydromorphone, oxycodone (option, expert
agreement).
There are no validated criteria to guide drug selection when
undertaking an opioid rotation, apart from the individual
precautions for use of each drug and the relative contraindi-
cations for each individual opioid (recommendation, expert
agreement).
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increased does not always necessitate opioid rotation (recommen-
dation, expert agreement).
Opioid rotation should take into consideration equianalgesic
doses, but it is always advisable to favour safety over rapid action
by using the lowest value of the conversion range (recommenda-
tion, expert agreement).
Precautions for use, compatibility, drug combinations and
opioids
When administering opioids parenterally, the physicochemical
compatibility with all other drugs needs to be taken into
consideration, as well as the risk of side effects arising from the
combination (standard, expert agreement).
In the event of metabolic failure, particularly liver or renal, the
same precautions should be taken for WHO level 2 and 3 opioids
(standard, expert agreement).
In the event of metabolic failure, opioids should be prescribed
with caution taking the following into account (recommendation,
expert agreement):
 selection of opioids taking into consideration their preferential
metabolic pathway and active metabolites;
 administration of oral or parenteral immediate-release forms;
 administration of lower doses (much lower doses may be
appropriate depending on the extent of the metabolic failure);
 cautious titration taking into consideration the efficacy and
duration of action of the first dose to calculate the subsequent
doses and intervals. After a few days of a stable dose, it may be
possible to consider using a sustained-release formulation with
adjustment, if necessary, of the rescue dose.
Rapid or immediate release formulations should be used initially
in patients with a short or irradiated small intestine (recommen-
dation, expert agreement). In elderly patients, lower doses and/or
longer intervals between the doses is recommended. Dose titration,
following the above rules, will facilitate pain control (recommen-
dation, expert agreement).
Actions to be taken in the event of opioid overdosage
Overdosage with oral morphine, and with opioids in general, is
characterised mainly by increasing drowsiness. This is accom-
panied by respiratory failure, seen as respiratory depression and
an increased expiratory pause (risk of apnoea).
Treatment of severe respiratory depression (respiratory fre-
quency less than about 8min
1) principally involves stopping
opioid treatment, stimulating the patient, oxygen therapy, and the
injection of an opioid-antagonist (naloxone). Constant surveillance
is required. Transfer to a medical intensive care unit may be
necessary, particularly if the patient is at home (standard, expert
agreement).
In the absence of a published, validated administration protocol
for naloxone, the following protocol is recommended (recommen-
dation, expert agreement):
 prepare an ampoule of 1ml (0.4mg) diluted to 10ml with a 5%
saline or glucose solution;
 give an intravenous injection of 1ml every 2min until the
respiratory frequency increases to 10min
1. This titration aims
to eliminate the respiratory depression, but not the analgesia;
 infuse two ampoules diluted in 250ml over 3–4h, repeat if
necessary, depending on the respiratory frequency and taking
into consideration the elimination time of the drug responsible
for the overdosage.
In other situations of overdosage, a ‘therapeutic window’,
adapted to the drug’s half-life and the intensity of the symptoms,
should be identified (standard, expert agreement).
If in the slightest doubt, the patient should be referred to an
anaesthetist for supervision of treatment and follow-up (standard,
expert agreement).
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